CN103083687B - A kind of silver, platinum cluster are in the application of cancer target imaging - Google Patents
A kind of silver, platinum cluster are in the application of cancer target imaging Download PDFInfo
- Publication number
- CN103083687B CN103083687B CN201310015357.2A CN201310015357A CN103083687B CN 103083687 B CN103083687 B CN 103083687B CN 201310015357 A CN201310015357 A CN 201310015357A CN 103083687 B CN103083687 B CN 103083687B
- Authority
- CN
- China
- Prior art keywords
- silver
- application
- imaging
- platinum cluster
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 title claims abstract description 69
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 48
- 229910052709 silver Inorganic materials 0.000 title claims abstract description 37
- 239000004332 silver Substances 0.000 title claims abstract description 37
- 229910052697 platinum Inorganic materials 0.000 title claims abstract description 35
- 238000003384 imaging method Methods 0.000 title claims abstract description 27
- 201000011510 cancer Diseases 0.000 title claims abstract description 15
- 238000011580 nude mouse model Methods 0.000 claims abstract description 34
- 239000000243 solution Substances 0.000 claims abstract description 32
- 238000002347 injection Methods 0.000 claims abstract description 23
- 239000007924 injection Substances 0.000 claims abstract description 23
- 238000002059 diagnostic imaging Methods 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 10
- 238000004451 qualitative analysis Methods 0.000 claims abstract description 8
- 238000004445 quantitative analysis Methods 0.000 claims abstract description 8
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 31
- 239000012216 imaging agent Substances 0.000 claims description 7
- XEVRDFDBXJMZFG-UHFFFAOYSA-N carbonyl dihydrazine Chemical compound NNC(=O)NN XEVRDFDBXJMZFG-UHFFFAOYSA-N 0.000 claims description 6
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 6
- 238000004113 cell culture Methods 0.000 claims description 5
- 210000003462 vein Anatomy 0.000 claims description 5
- PTNQDPSRUQFPEZ-GEMLJDPKSA-N (2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid;silver Chemical compound [Ag].OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O PTNQDPSRUQFPEZ-GEMLJDPKSA-N 0.000 claims description 4
- 239000012531 culture fluid Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 238000005481 NMR spectroscopy Methods 0.000 claims description 3
- 238000001069 Raman spectroscopy Methods 0.000 claims description 3
- 238000013170 computed tomography imaging Methods 0.000 claims description 3
- 238000000799 fluorescence microscopy Methods 0.000 claims description 3
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 3
- 238000010254 subcutaneous injection Methods 0.000 claims description 3
- 239000007929 subcutaneous injection Substances 0.000 claims description 3
- 238000001931 thermography Methods 0.000 claims description 3
- 206010064571 Gene mutation Diseases 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 230000002269 spontaneous effect Effects 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims description 2
- 238000002255 vaccination Methods 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 abstract description 4
- 239000002245 particle Substances 0.000 abstract description 4
- 230000008685 targeting Effects 0.000 abstract description 2
- 230000000007 visual effect Effects 0.000 abstract description 2
- 241000699660 Mus musculus Species 0.000 description 13
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000002086 nanomaterial Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- PLKATZNSTYDYJW-UHFFFAOYSA-N azane silver Chemical compound N.[Ag] PLKATZNSTYDYJW-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 238000012984 biological imaging Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000005543 nano-size silicon particle Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- -1 platinum ion Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
- A61K49/0414—Particles, beads, capsules or spheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/225—Microparticles, microcapsules
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Acoustics & Sound (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses a kind of silver, the application of platinum cluster in cancer target imaging, concrete steps are: first build nude mouse tumor model; Then to local injection in nude mouse through the silver of ultrasonic disperse or platinum cluster, or direct injection 0.1-100 μ? mol/L Ag-containing solution or platiniferous solution; After injection 24h, with medical imaging procedure medical imaging is carried out to nude mouse tumor position and imaging results is carried out qualitative and quantitative analysis.The silver that the present invention obtains, platinum cluster particle diameter are little, good penetrability, fluorescent stability are high, highly sensitive, targeting strong, can realize the accurate location to tumor; Silver of the present invention, platinum cluster are directly synthesized by organism, have good biocompatibility; Silver, platinum cluster injects after ultrasonic disperse, make nano-particle thinner evenly, be more conducive to absorbing; The present invention is easy to operate, visual result.
Description
Technical field
The present invention relates to silver, platinum cluster as the application of tumor imaging agent in cancer target imaging, the present invention is applicable to medical imaging field.
Background technology
Living body biological imaging technique is the strong means of molecule and cell event in test experience animal body, be applied to medical science and biological study field more and more widely, there is high detection sensitivity and cheap experimental expenses, but accurately can obtain the experimental result of expection with the least possible size of animal extremely short time planted agent, for researcher provides wide application space, but still there is many limitation in this technology, the tissue autofluorescence produced during illumination especially in vivo and the weak tissue permeability under disconnected ripple excitation light irradiation.
In order to overcome these difficulties.Scientist have studied a series of inorganic light-emitting nano material, some inorganic nano materials, as nano silicon particles because its some excellent character are used widely in bioanalysis and imaging, but still there are some problems, most important is exactly the size of nano-particle.Grain diameter is less, and the probability that granule is absorbed by epithelial reticular tissue system is less, and excretes more easily by urinary system, thus has better biocompatibility.In addition, when carrying out targeted imaging to tumor, the little nano material of particle diameter more easily by EPR effect passive target to tumor locus thus the accurate location realized tumor.
Chinese patent CN102735752A discloses the application of gold nanoclusters on cancer target living imaging, does not also have silver at present, documents and materials that platinum cluster is applied to cancer target imaging.
Summary of the invention
Goal of the invention: the object of the present invention is to provide that a kind of particle diameter is little, the application in cancer target imaging of the silver of good biocompatibility, platinum cluster.
Technical scheme: principle of the present invention is certain density silver, platinum ion can synthesis of nano bunch and in tumor locus enrichment in vivo, can checkout and diagnosis tumor locus by medical imaging.Specifically, silver, the applying step of platinum cluster in cancer target imaging are:
(1) nude mouse tumor model is built;
(2) to local injection in nude mouse through the silver of ultrasonic disperse or platinum cluster, or direct injection 0.1-100 μm of ol/L Ag-containing solution or platiniferous solution;
(3) inject after 24h, with medical imaging procedure medical imaging is carried out to nude mouse tumor position and imaging results is carried out qualitative and quantitative analysis.
Culture fluid containing 0.1-100 μm of ol/L Ag-containing solution or platiniferous solution and the cell or tissue cultivating 24h are jointly hatched 10-72 hour in cell culture incubator, silver or platinum cluster can be formed in culture fluid, silver or platinum cluster granule silver in culture fluid or platinum cluster can be made after ultrasonic disperse instrument ultrasonic disperse thinner, be injected in nude mouse and nano-cluster granule can be made to be more evenly distributed in nude mouse.
Directly to injecting Ag-containing solution or platiniferous solution in nude mouse, can in nude mouse synthesis of nano bunch and in tumor locus enrichment, there is good biocompatibility.
Described Ag-containing solution is silver ammino solution, silver nitrate or glutathion silver solution.
Described platiniferous solution is cis diaminourea two network platinum solution or trans diaminourea two network platinum solution.
Described medical imaging procedure is fluorescence imaging, NMR (Nuclear Magnetic Resonance) imaging, Raman image, CT imaging, thermal imaging or ultra sonic imaging.
Described local injection mode is local subcutaneous injection, intradermal injection, intramuscular injection, tail vein injection or lumbar injection.
Nude mouse tumor model is Orthotopic transplanted tumor model, original position transfer tumor model, subcutaneous vaccination tumor model, drug-induced tumor model, gene mutation tumor model or Spontaneous Tumor model.
Beneficial effect: compared with prior art, remarkable advantage of the present invention is:
(1) the present invention obtain silver, platinum cluster particle diameter is little, good penetrability, fluorescent stability are high, highly sensitive, targeting is strong, can realize the accurate location to tumor;
(2) silver of the present invention, platinum cluster are directly synthesized by organism, have good biocompatibility;
(3) silver of the present invention, platinum cluster are injected after ultrasonic disperse, make nano-particle thinner evenly, be more conducive to absorbing;
(4) easy to operate, the visual result of the present invention, earlier detection and diagnosis can be carried out to tumor, also can be applied in the researchs such as the vivo tumor tracing study imaging such as deep tumor, large animal, there is the using value that potential clinical disease follows the trail of therapeutic imaging.
Accompanying drawing explanation
Fig. 1 a is the embodiment of the present invention 1 experimental group confocal fluorescent microscopy images figure;
Fig. 1 b is the embodiment of the present invention 1 matched group confocal fluorescent microscopy images figure;
Fig. 2 is the embodiment of the present invention 2 nude mice fluorescence imaging cancer target image.
Detailed description of the invention
Embodiment 1
Select hepatoma carcinoma cell (HepG2) as object of study, experimental group will be in the hepatoma carcinoma cell (HepG2) of exponential phase according to 1.6 × 10
5the density of individual cells/well is inoculated in 6 orifice plates, adds sterilizing and carry out the diluted glutathion contained silver ammonia 1 μm of ol/L solution by the DMEM culture medium of fresh sterile after cultivating 24h.
Matched group by the hepatoma carcinoma cell (HepG2) in culture medium according to 1.6 × 10
5the density of individual cells/well is inoculated in 6 orifice plates, cultivates 24h.Every hole that incubation time stops backward experimental group and matched group adds phosphate buffer solution (PBS, pH=7.4) and rinses 2-3 time.Then carry out observation with Laser Scanning Confocal Microscope to detect.Experimental group experimental result as shown in Figure 1a, can be observed the gathering of silver nano-grain, and matched group experimental result as shown in Figure 1 b, does not observe nano-particle.
Embodiment 2
Build nude mice by subcutaneous inoculation breast cancer model, breast cancer cell adds sterilizing after cultivating 24h and carries out the glutathion silver ammino solution of 0.1 μm of diluted ol/L by the DMEM culture medium of fresh sterile, 24 hours obtained silver nanoclusters are hatched in cell culture incubator, after the solution ultrasonic disperse containing silver nanoclusters, be expelled in nude mouse by tail vein injection method, after 24h, living body fluorescent imaging is carried out to nude mice.Experiment shows that silver nanoclusters can realize targeted imaging to tumor locus.Experimental result as shown in Figure 2.
Embodiment 3
Build hepatocellular carcinoma in nude mice orthotopic implantation model, hepatoma carcinoma cell adds sterilizing after cultivating 24h and carries out the cis diaminourea two network platinum solution of 50 μm of diluted ol/L by the DMEM culture medium of fresh sterile, 48 hours obtained platinum clusters are hatched in cell culture incubator, after the solution ultrasonic disperse containing platinum cluster, by local subcutaneous injection injection in nude mouse, after 24h, NMR (Nuclear Magnetic Resonance) imaging is carried out to nude mice and imaging results is carried out qualitative and quantitative analysis.
Embodiment 4
Build the drug-induced ovarian tumor model of nude mice, ovarian cancer cell adds sterilizing after cultivating 24h and carries out the silver nitrate solution of 100 μm of diluted ol/L by the DMEM culture medium of fresh sterile, 72 hours obtained silver nanoclusters are hatched in cell culture incubator, after the solution ultrasonic disperse containing silver nanoclusters, be expelled in nude mouse by lumbar injection, after 24h, Raman image is carried out to nude mice and imaging results is carried out qualitative and quantitative analysis.
Embodiment 5
Build nude mice by subcutaneous inoculation breast cancer model, by the silver ammino solution of tail vein injection method direct injection 0.1 μm of ol/L in nude mouse, after 24h, CT imaging is carried out to nude mice and imaging results is carried out qualitative and quantitative analysis.
Embodiment 6
Build hepatocellular carcinoma in nude mice orthotopic implantation model, by the trans diaminourea two network platinum solution of intradermal injection method direct injection 50 μm of ol/L in nude mouse, after 24h, thermal imaging is carried out to nude mice and imaging results is carried out qualitative and quantitative analysis.
Embodiment 7
Build the drug-induced ovarian tumor model of nude mice, by the glutathion silver solution of tail vein injection method direct injection 100 μm of ol/L in nude mouse, after 24h, ultra sonic imaging is carried out to nude mice and imaging results is carried out qualitative and quantitative analysis.
Claims (6)
1. silver, platinum cluster are in the application of Application and preparation in cancer target imaging agent, it is characterized in that: concrete steps are:
(1) nude mouse tumor model is built;
(2) to local injection in nude mouse through the silver of ultrasonic disperse or platinum cluster;
(3) inject after 24h, with medical imaging procedure medical imaging is carried out to nude mouse tumor position and imaging results is carried out qualitative and quantitative analysis;
Described silver or platinum cluster be by by the culture fluid containing 0.1-100 μm of ol/L Ag-containing solution or platiniferous solution with cultivate the cell or tissue of 24h in cell culture incubator, jointly hatch 24-72 hour obtained silver or platinum cluster.
2. silver as claimed in claim 1, platinum cluster are in the application of Application and preparation in cancer target imaging agent, it is characterized in that: described Ag-containing solution is silver ammino solution, silver nitrate or glutathion silver solution.
3. silver as claimed in claim 1, platinum cluster are in the application of Application and preparation in cancer target imaging agent, it is characterized in that: described platiniferous solution is cis diaminourea two network platinum solution or trans diaminourea two network platinum solution.
4. silver as claimed in claim 1, platinum cluster are in the application of Application and preparation in cancer target imaging agent, it is characterized in that: described medical imaging procedure is fluorescence imaging, NMR (Nuclear Magnetic Resonance) imaging, Raman image, CT imaging, thermal imaging or ultra sonic imaging.
5. silver as claimed in claim 1, platinum cluster are in the application of Application and preparation in cancer target imaging agent, it is characterized in that: described local injection mode is local subcutaneous injection, intradermal injection, intramuscular injection, tail vein injection or lumbar injection.
6. silver as claimed in claim 1, platinum cluster are in the application of Application and preparation in cancer target imaging agent, it is characterized in that: described nude mouse tumor model is Orthotopic transplanted tumor model, original position transfer tumor model, subcutaneous vaccination tumor model, drug-induced tumor model, gene mutation tumor model or Spontaneous Tumor model.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310015357.2A CN103083687B (en) | 2013-01-16 | 2013-01-16 | A kind of silver, platinum cluster are in the application of cancer target imaging |
| PCT/CN2013/072344 WO2014110863A1 (en) | 2013-01-16 | 2013-03-08 | Application of silver and platinum nano-cluster in tumor targeted imaging |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310015357.2A CN103083687B (en) | 2013-01-16 | 2013-01-16 | A kind of silver, platinum cluster are in the application of cancer target imaging |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103083687A CN103083687A (en) | 2013-05-08 |
| CN103083687B true CN103083687B (en) | 2016-04-13 |
Family
ID=48197158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310015357.2A Active CN103083687B (en) | 2013-01-16 | 2013-01-16 | A kind of silver, platinum cluster are in the application of cancer target imaging |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN103083687B (en) |
| WO (1) | WO2014110863A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103861124B (en) * | 2014-03-03 | 2016-09-21 | 东南大学 | The preparation method of platinum cluster and the application in the preparation and apoptosis agent of tumor |
| CN105214103B (en) * | 2015-10-14 | 2018-04-24 | 东南大学 | For malignant tumour and the metal ion reagent and image preparation of the quick detection of cardiovascular and cerebrovascular relevant disease early stage and multi-modality imaging |
| CN107184981A (en) * | 2017-06-08 | 2017-09-22 | 浙江大学 | A kind of sheet Triangular Silver nanoparticle antibacterial suspension and its preparation method and application |
| CN107884377B (en) * | 2017-11-24 | 2020-09-11 | 东南大学 | Cell exosome-based nanocluster probe and application thereof in preparation of imaging preparation |
| CN108865147B (en) * | 2018-06-01 | 2021-05-18 | 福州大学 | Erlotinib-protected platinum-silver nano-cluster and preparation method thereof |
| CN109266333B (en) * | 2018-10-23 | 2020-06-12 | 山西大学 | Preparation method and application of fluorescent silver nanocluster probe |
| CN111592875B (en) * | 2020-02-08 | 2023-04-18 | 安徽师范大学 | Fluorescent cellulase platinum nanocluster and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1909931A (en) * | 2004-01-15 | 2007-02-07 | 皇家飞利浦电子股份有限公司 | Ultrasound contrast agents for molecular imaging |
| CN102203002A (en) * | 2007-09-21 | 2011-09-28 | 细胞免疫科学公司 | Nanotherapeutic colloidal metal compositions and methods |
| CN102703060A (en) * | 2012-06-08 | 2012-10-03 | 中国药科大学 | Targeted tracing noble metal fluorescence probe and anti-tumor prodrug |
| CN102735752A (en) * | 2012-06-11 | 2012-10-17 | 东南大学 | Tumor-targeting living body multimodality imaging method based on gold nano-clusters |
-
2013
- 2013-01-16 CN CN201310015357.2A patent/CN103083687B/en active Active
- 2013-03-08 WO PCT/CN2013/072344 patent/WO2014110863A1/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1909931A (en) * | 2004-01-15 | 2007-02-07 | 皇家飞利浦电子股份有限公司 | Ultrasound contrast agents for molecular imaging |
| CN102203002A (en) * | 2007-09-21 | 2011-09-28 | 细胞免疫科学公司 | Nanotherapeutic colloidal metal compositions and methods |
| CN102703060A (en) * | 2012-06-08 | 2012-10-03 | 中国药科大学 | Targeted tracing noble metal fluorescence probe and anti-tumor prodrug |
| CN102735752A (en) * | 2012-06-11 | 2012-10-17 | 东南大学 | Tumor-targeting living body multimodality imaging method based on gold nano-clusters |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014110863A1 (en) | 2014-07-24 |
| CN103083687A (en) | 2013-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103083687B (en) | A kind of silver, platinum cluster are in the application of cancer target imaging | |
| CN102735752B (en) | Tumor-targeting living body multimodality imaging method based on gold nano-clusters | |
| Stuker et al. | Fluorescence molecular tomography: principles and potential for pharmaceutical research | |
| CN103330948B (en) | Tumor targeted living body rapid fluorescence imaging method of rare earth metal nanocluster | |
| CN103212056A (en) | Preparation based on gold, silver, gold-silver mixture and glutathione/chitosan, and application of preparation | |
| Seth et al. | Current perspective on in vivo molecular imaging of immune cells | |
| CN103820106A (en) | Green synthetic method of fluorescence copper nano-cluster, and application of fluorescence copper nano-cluster | |
| Wuttisarnwattana et al. | Cryo-imaging of stem cell biodistribution in mouse model of graft-versus-host-disease | |
| Chen et al. | Stem cell tracking with nanoparticle-based ultrasound contrast agents | |
| Chen et al. | New researches and application progress of commonly used optical molecular imaging technology | |
| CN103143037B (en) | Method for synthesizing rare earth metal compound nano cluster and application thereof | |
| Kim et al. | Magneto-acoustic protein nanostructures for non-invasive imaging of tissue mechanics in vivo | |
| Dunn et al. | Functional studies in living animals using multiphoton microscopy | |
| Shirokov et al. | Different Effects of Phototherapy for Rat Glioma during Sleep and Wakefulness | |
| CN103099604B (en) | An imaging method of tumor targeting based on enhancement effect of zinc ion signals | |
| CN108434469A (en) | A kind of HER2 affinities body68Ga markers and preparation method thereof, application | |
| CN101003792A (en) | Constructing 9LLUC cell strain of expressing luciferase stably, and application | |
| CN106512029A (en) | Nano-probe with apoptosis target function and preparation and application | |
| CN112553166A (en) | Living body imaging technology-based 2-type diabetes mouse pancreatic cancer model construction method | |
| Xiong et al. | In vivo monitoring the process of tumor growth, metastasis and bacterial infection expressing GFP via real-time optical imaging | |
| Théodorou et al. | In vitro and in vivo imaging of fluorescent aptamers | |
| CN103834740B (en) | The apoptotic HSV1-TK molecular image probe of a kind of detection | |
| Hudson | The welfare and scientific advantages of non-invasive imaging of animals used in biomedical research | |
| Chicote et al. | Advanced colorectal cancer orthotopic patient-derived xenograft models for cancer and stem cell research | |
| Xu et al. | CT/FMT dual-model imaging of breast cancer based on peptide-lipid nanoparticles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |